search
Back to results

Bowel Cleansing Performance of the Pure-Vu System in Patients With a History of Poor Bowel Preparation

Primary Purpose

Colorectal Cancer, Colonic Adenoma, Bowel Preparation

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Pure-Vu System
Sponsored by
Radboud University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Colorectal Cancer focused on measuring Bowel preparation, colonoscopy, colorectal cancer, adenoma detection rate, endoscopy, therapeutic irrigation

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients, aged between 18 and 80 years, referred and scheduled for either screening, diagnostic, or surveillance colonoscopy.
  • Poor bowel preparation within the last 2 years, defined as a BBPS <6 or need for repeat colonoscopy or shortening of surveillance interval due to poor bowel preparation

Exclusion Criteria:

  • Prior colon resection
  • Previous colorectal cancer
  • Colitis
  • Lower gastrointestinal bleeding with hemodynamic instability
  • Bowel obstruction
  • Pregnancy or lactating
  • ASA > 3
  • Insufficiently corrected anticoagulation disorders
  • Inability to provide informed consent

Sites / Locations

  • University Medical Center Mainz
  • Radboud university medical center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Pure-Vu

Arm Description

All patients willing to participate will receive a limited bowel preparation (2-days of dietary restrictions + 2x 150ml picoprep) followed by intra-procedural bowel cleansing with the Pure-Vu System (single arm)

Outcomes

Primary Outcome Measures

Boston Bowel Preparation scale (BBPS)-score before cleaning with the Pure-Vu system.
Boston Bowel Preparation scale (BBPS): The adequacy of bowel preparation should be assessed after all appropriate efforts to clear residual debris is completed. All three bowel regions of the colon will be scored (i.e., the right colon, transverse colon, and left colon) from 0-3 points by the endoscopist. The segment scores are summed for a total BBPS ranging from 0 to 9. The points will be assigned as follows: 0) Unprepared colon segment with mucosa not seen because of solid stool that could not be cleared. Portion of mucosa of the colon segment seen, but other areas of the colon segment are not well seen because of staining, residual stool, and/or opaque liquid. Minor amount of residual staining, small fragments of stool, and/or opaque liquid but mucosa of colon segment seen well. Entire mucosa of colon segment seen well, with no residual staining, small fragments of stool, or opaque liquid. Each segment of the colon received a segmental score from 0- 3.
Boston Bowel Preparation scale (BBPS)-score after cleaning with the Pure-Vu system.
Boston Bowel Preparation scale (BBPS): The adequacy of bowel preparation should be assessed after all appropriate efforts to clear residual debris is completed. All three bowel regions of the colon will be scored (i.e., the right colon, transverse colon, and left colon) from 0-3 points by the endoscopist. The segment scores are summed for a total BBPS ranging from 0 to 9. The points will be assigned as follows: 0) Unprepared colon segment with mucosa not seen because of solid stool that could not be cleared. Portion of mucosa of the colon segment seen, but other areas of the colon segment are not well seen because of staining, residual stool, and/or opaque liquid. Minor amount of residual staining, small fragments of stool, and/or opaque liquid but mucosa of colon segment seen well. Entire mucosa of colon segment seen well, with no residual staining, small fragments of stool, or opaque liquid. Each segment of the colon received a segmental score from 0- 3.

Secondary Outcome Measures

Total number of colon lesions specified by histology
Adenoma detection rate
Cecal intubation rates
Procedure times (total procedure time, cecal intubation time, withdrawal time, time for all other interventions)
Total amount of water used for washing and total amount of fluids+residual stool removed.
Patient reported outcomes (level of discomfort during bowel preparation and during colonoscopy on a visual analog scale)
A visual analogue scale from 0 to 10, in which higher numbers indicate a higher level of discomfort.
System usability
general ease of use, ease of rectum insertion, ease of angulation, ease of advancement, device stiffness, ease of polyp resection holding forces, ease of retroflexion, Unacceptable Difficult Acceptable Good (as good as conventional colonoscopy) Excellent
Endoscopists' learning curve
Number of adverse events after study intervention
Safety outcomes (adverse events): Severe adverse events will be subcategorized cardiac (cardiac ischemia, heart failure, arrhythmia, other) pulmonary (exacerbation of Chronic Obstructive Pulmonary Disease, infectious, other), neurological (stroke, cerebrovascular accident, bleeding, other), and other (surgical interventions etc.).

Full Information

First Posted
December 17, 2020
Last Updated
August 8, 2022
Sponsor
Radboud University Medical Center
Collaborators
University Medical Center Mainz, Motus GI Medical Technologies Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT04700410
Brief Title
Bowel Cleansing Performance of the Pure-Vu System in Patients With a History of Poor Bowel Preparation
Official Title
A New Method for Bowel Cleansing in Patients With a History of Poor Bowel Preparation - A Multicenter Feasibility Study With the Pure-Vu System
Study Type
Interventional

2. Study Status

Record Verification Date
August 2022
Overall Recruitment Status
Completed
Study Start Date
June 1, 2021 (Actual)
Primary Completion Date
March 28, 2022 (Actual)
Study Completion Date
May 1, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Radboud University Medical Center
Collaborators
University Medical Center Mainz, Motus GI Medical Technologies Ltd

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The diagnostic accuracy and safety of colonoscopy highly depends on the quality of the pre-procedural bowel preparation. A past history of poor bowel preparation is the most important risk factor of inadequate bowel cleansing at the next colonoscopy. This study aims to evaluate if an adequate level of bowel cleansing can be achieved with the Pure-Vu System in patients with previous poor bowel preparation, in a single arm international multicenter feasibility study.
Detailed Description
Rationale: It is widely acknowledged that the efficacy and safety of colonoscopy depends on the quality of the pre-procedural bowel preparation. Despite its importance, the proportion of colonoscopies with inadequate bowel preparation still ranges from 6.8-33% across studies. A past history of poor bowel preparation is the most important risk factor of inadequate bowel cleansing at the next colonoscopy. (1, 2) Evidence to recommend a specific bowel cleansing regimen in these patients is currently lacking. (3) Mostly, patients with previous bowel preparation are advised to drink more oral purgatives, which is very difficult and unpleasant for patients and therefore often fails. The aim of this study is to evaluate if an intra-procedural bowel cleaning device, the Pure-VuTM System (Tirat Carmel, Israel) can be used to achieve an adequate level of bowel cleansing in patients with previous poor bowel preparation. Objective: The aim of this study is to evaluate if an adequate level of bowel cleansing can be achieved with the Pure-Vu System in patients with previous poor bowel preparation (Boston Bowel Preparation Scale [BBPS]<6). Study design: We will perform a single arm international multicenter colonoscopy trial. Adult patients with previous poor bowel preparation (BBPS<6) will be invited to participate in our study (n= 44). All patients willing to participate will receive a limited bowel preparation (2-days of dietary restrictions + 2x 150ml picoprep) followed by intra-procedural bowel cleansing with the Pure-Vu System. The BBPS will be assessed before and after segmental washing by the endoscopist who performs the procedure and later by an independent endoscopist (photos). Study population: Adult patients with poor bowel preparation within the last 2 years. Exclusion criteria; previous colon resection, previous colorectal cancer, colitis, lower gastrointestinal bleeding with hemodynamic instability, ASA>3, insufficiently corrected anticoagulation disorders, inability to provide informed consent. Primary endpoint: The primary endpoint of the study will be the BBPS-score before and after intra-procedural bowel cleaning with the Pure-Vu System. Secondary endpoints include: Total number of colon lesions specified by histology Adenoma detection rate Cecal intubation rates Procedure times (total procedure time, cecal intubation time, withdrawal time, time for all other interventions) Total amount of water used for washing and total amount of fluids+residual stool removed. Patient reported outcomes (level of discomfort during bowel preparation and during colonoscopy on a visual analog scale) System usability Endoscopists' learning curve Safety outcomes Nature and extent of the burden and risk associated with participation, benefit and group relatedness: Colonoscopy is a commonly performed procedure and the overall serious adverse event (SAE) rate is low, around 2.8 per 1000 colonoscopies. The risk of adverse events (AE) with the Pure-Vu are believed to be equivalent to conventional colonoscopy, including bleeding and perforation risks (13). Participation in this study could potentially benefit colonoscopy patients because the Pure-Vu is expected to improve the quality of colonoscopy. Inadequate bowel cleansing may be prevented by the Pure-Vu System. Inadequate bowel cleansing is associated with lower adenoma detection rates (ADR), lower completion rates, longer procedure times, more complications and a higher need for repeat procedures.(4, 5) In addition, Pure-Vu reduces the reliance on patients pre-procedural bowel preparation which is often considered the most deterrent part of colonoscopy by patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colorectal Cancer, Colonic Adenoma, Bowel Preparation
Keywords
Bowel preparation, colonoscopy, colorectal cancer, adenoma detection rate, endoscopy, therapeutic irrigation

7. Study Design

Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
single arm international multicenter colonoscopy trial
Masking
None (Open Label)
Masking Description
Independent assessment of BBPS (photos).
Allocation
N/A
Enrollment
44 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Pure-Vu
Arm Type
Experimental
Arm Description
All patients willing to participate will receive a limited bowel preparation (2-days of dietary restrictions + 2x 150ml picoprep) followed by intra-procedural bowel cleansing with the Pure-Vu System (single arm)
Intervention Type
Device
Intervention Name(s)
Pure-Vu System
Intervention Description
All patients willing to participate will receive a limited bowel preparation (2-days of dietary restrictions + 2x 150ml picoprep) followed by intra-procedural bowel cleansing with the Pure-Vu System.
Primary Outcome Measure Information:
Title
Boston Bowel Preparation scale (BBPS)-score before cleaning with the Pure-Vu system.
Description
Boston Bowel Preparation scale (BBPS): The adequacy of bowel preparation should be assessed after all appropriate efforts to clear residual debris is completed. All three bowel regions of the colon will be scored (i.e., the right colon, transverse colon, and left colon) from 0-3 points by the endoscopist. The segment scores are summed for a total BBPS ranging from 0 to 9. The points will be assigned as follows: 0) Unprepared colon segment with mucosa not seen because of solid stool that could not be cleared. Portion of mucosa of the colon segment seen, but other areas of the colon segment are not well seen because of staining, residual stool, and/or opaque liquid. Minor amount of residual staining, small fragments of stool, and/or opaque liquid but mucosa of colon segment seen well. Entire mucosa of colon segment seen well, with no residual staining, small fragments of stool, or opaque liquid. Each segment of the colon received a segmental score from 0- 3.
Time Frame
1 day (day of intervention)
Title
Boston Bowel Preparation scale (BBPS)-score after cleaning with the Pure-Vu system.
Description
Boston Bowel Preparation scale (BBPS): The adequacy of bowel preparation should be assessed after all appropriate efforts to clear residual debris is completed. All three bowel regions of the colon will be scored (i.e., the right colon, transverse colon, and left colon) from 0-3 points by the endoscopist. The segment scores are summed for a total BBPS ranging from 0 to 9. The points will be assigned as follows: 0) Unprepared colon segment with mucosa not seen because of solid stool that could not be cleared. Portion of mucosa of the colon segment seen, but other areas of the colon segment are not well seen because of staining, residual stool, and/or opaque liquid. Minor amount of residual staining, small fragments of stool, and/or opaque liquid but mucosa of colon segment seen well. Entire mucosa of colon segment seen well, with no residual staining, small fragments of stool, or opaque liquid. Each segment of the colon received a segmental score from 0- 3.
Time Frame
1 day (day of intervention)
Secondary Outcome Measure Information:
Title
Total number of colon lesions specified by histology
Time Frame
1 day (day of intervention)
Title
Adenoma detection rate
Time Frame
1 day (day of intervention)
Title
Cecal intubation rates
Time Frame
1 day (day of intervention)
Title
Procedure times (total procedure time, cecal intubation time, withdrawal time, time for all other interventions)
Time Frame
1 day (day of intervention)
Title
Total amount of water used for washing and total amount of fluids+residual stool removed.
Time Frame
1 day (day of intervention)
Title
Patient reported outcomes (level of discomfort during bowel preparation and during colonoscopy on a visual analog scale)
Description
A visual analogue scale from 0 to 10, in which higher numbers indicate a higher level of discomfort.
Time Frame
1 month
Title
System usability
Description
general ease of use, ease of rectum insertion, ease of angulation, ease of advancement, device stiffness, ease of polyp resection holding forces, ease of retroflexion, Unacceptable Difficult Acceptable Good (as good as conventional colonoscopy) Excellent
Time Frame
through study completion, an average of 1 year
Title
Endoscopists' learning curve
Time Frame
through study completion, an average of 1 year
Title
Number of adverse events after study intervention
Description
Safety outcomes (adverse events): Severe adverse events will be subcategorized cardiac (cardiac ischemia, heart failure, arrhythmia, other) pulmonary (exacerbation of Chronic Obstructive Pulmonary Disease, infectious, other), neurological (stroke, cerebrovascular accident, bleeding, other), and other (surgical interventions etc.).
Time Frame
48 hours and 1month after intervention

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients, aged between 18 and 80 years, referred and scheduled for either screening, diagnostic, or surveillance colonoscopy. Poor bowel preparation within the last 2 years, defined as a BBPS <6 or need for repeat colonoscopy or shortening of surveillance interval due to poor bowel preparation Exclusion Criteria: Prior colon resection Previous colorectal cancer Colitis Lower gastrointestinal bleeding with hemodynamic instability Bowel obstruction Pregnancy or lactating ASA > 3 Insufficiently corrected anticoagulation disorders Inability to provide informed consent
Facility Information:
Facility Name
University Medical Center Mainz
City
Mainz
Country
Germany
Facility Name
Radboud university medical center
City
Nijmegen
State/Province
Gelderland
ZIP/Postal Code
6525GA
Country
Netherlands

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
IPD will be shared upon reasonable request
IPD Sharing Access Criteria
Data will be shared upon reasonable request

Learn more about this trial

Bowel Cleansing Performance of the Pure-Vu System in Patients With a History of Poor Bowel Preparation

We'll reach out to this number within 24 hrs